BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013;8:e76781. [PMID: 24204673 DOI: 10.1371/journal.pone.0076781] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Lin C, Zhang J. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018;1869:200-15. [DOI: 10.1016/j.bbcan.2018.01.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
2 Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Seminars in Immunology 2017;31:37-54. [DOI: 10.1016/j.smim.2017.07.009] [Cited by in Crossref: 125] [Cited by in F6Publishing: 124] [Article Influence: 31.3] [Reference Citation Analysis]
3 Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 2016;128:297-312. [PMID: 27247137 DOI: 10.1182/blood-2016-03-706317] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
4 Sivori S, Meazza R, Quintarelli C, Carlomagno S, Della Chiesa M, Falco M, Moretta L, Locatelli F, Pende D. NK Cell-Based Immunotherapy for Hematological Malignancies. J Clin Med 2019;8:E1702. [PMID: 31623224 DOI: 10.3390/jcm8101702] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
5 [DOI: 10.1101/2020.03.30.016667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Valipour B, Velaei K, Abedelahi A, Karimipour M, Darabi M, Charoudeh HN. NK cells: An attractive candidate for cancer therapy. J Cell Physiol 2019;234:19352-65. [DOI: 10.1002/jcp.28657] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
7 Lusty E, Poznanski SM, Kwofie K, Mandur TS, Lee DA, Richards CD, Ashkar AA. IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. Mol Immunol 2017;88:138-47. [PMID: 28644973 DOI: 10.1016/j.molimm.2017.06.025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
8 Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther 2021;12:211. [PMID: 33766099 DOI: 10.1186/s13287-021-02277-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L, Bruno B. Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Front Immunol 2017;8:1444. [PMID: 29163516 DOI: 10.3389/fimmu.2017.01444] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
10 Mehta RS, Rezvani K. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Front Immunol 2018;9:283. [PMID: 29497427 DOI: 10.3389/fimmu.2018.00283] [Cited by in Crossref: 131] [Cited by in F6Publishing: 130] [Article Influence: 43.7] [Reference Citation Analysis]
11 Liu P, Jin Y, Sattar H, Liu H, Xie W, Zhou F. Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities. J Leukoc Biol 2018;103:821-8. [DOI: 10.1002/jlb.2ru0517-176rr] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother 2015;38:24-36. [PMID: 25415285 DOI: 10.1097/CJI.0000000000000059] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 15.3] [Reference Citation Analysis]
13 Baggio L, Laureano ÁM, Silla LMDR, Lee DA. Natural killer cell adoptive immunotherapy: Coming of age. Clinical Immunology 2017;177:3-11. [DOI: 10.1016/j.clim.2016.02.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
14 Ishii K, Barrett AJ. Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol 2016;7:17-39. [PMID: 26834952 DOI: 10.1177/2040620715616544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
15 Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 2018;32:520-31. [PMID: 28725044 DOI: 10.1038/leu.2017.226] [Cited by in Crossref: 250] [Cited by in F6Publishing: 236] [Article Influence: 62.5] [Reference Citation Analysis]
16 Corral Sánchez MD, Fernández Casanova L, Pérez-Martínez A. Beyond CAR-T cells: Natural killer cells immunotherapy. Med Clin (Barc) 2020;154:134-41. [PMID: 31771858 DOI: 10.1016/j.medcli.2019.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Choi JW, Lee ES, Kim SY, Park SI, Oh S, Kang JH, Ryu HA, Lee S. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer. BMC Cancer 2019;19:817. [PMID: 31426763 DOI: 10.1186/s12885-019-6034-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Li K, Wu Y, Li Y, Yu Q, Tian Z, Wei H, Qu K. Landscape and Dynamics of the Transcriptional Regulatory Network During Natural Killer Cell Differentiation. Genomics Proteomics Bioinformatics 2020;18:501-15. [PMID: 33385611 DOI: 10.1016/j.gpb.2020.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol 2020;13:168. [PMID: 33287875 DOI: 10.1186/s13045-020-00998-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 25.0] [Reference Citation Analysis]
20 Vasu S, Berg M, Davidson-Moncada J, Tian X, Cullis H, Childs RW. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Cytotherapy 2015;17:1582-93. [PMID: 26432560 DOI: 10.1016/j.jcyt.2015.07.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
21 Martín-Antonio B, Suñe G, Najjar A, Perez-Amill L, Antoñana-Vildosola A, Castella M, León S, Velasco-de Andrés M, Lozano F, Lozano E, Bueno C, Estanyol JM, Muñoz-Pinedo C, Robinson SN, Urbano-Ispizua A. Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. J Immunother Cancer 2019;7:259. [PMID: 31619273 DOI: 10.1186/s40425-019-0739-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
22 Chabannon C, Mfarrej B, Guia S, Ugolini S, Devillier R, Blaise D, Vivier E, Calmels B. Manufacturing Natural Killer Cells as Medicinal Products. Front Immunol 2016;7:504. [PMID: 27895646 DOI: 10.3389/fimmu.2016.00504] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
23 Guo Y, Feng X, Jiang Y, Shi X, Xing X, Liu X, Li N, Fadeel B, Zheng C. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells. Oncotarget 2016;7:48360-74. [PMID: 27356741 DOI: 10.18632/oncotarget.10235] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
24 Rezvani K, Rouce RH. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol 2015;6:578. [PMID: 26635792 DOI: 10.3389/fimmu.2015.00578] [Cited by in Crossref: 141] [Cited by in F6Publishing: 143] [Article Influence: 23.5] [Reference Citation Analysis]
25 Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CRY, Bollard CM. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma. Clin Cancer Res 2019;25:4400-12. [PMID: 31010834 DOI: 10.1158/1078-0432.CCR-18-3183] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
26 Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opin Biol Ther 2018;18:121-34. [PMID: 29103317 DOI: 10.1080/14712598.2018.1402002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
27 Wu Y, Li Y, Fu B, Jin L, Zheng X, Zhang A, Sun R, Tian Z, Wei H. Programmed differentiated natural killer cells kill leukemia cells by engaging SLAM family receptors. Oncotarget 2017;8:57024-38. [PMID: 28915651 DOI: 10.18632/oncotarget.18659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lim O, Jung MY, Hwang YK, Shin EC. Present and Future of Allogeneic Natural Killer Cell Therapy. Front Immunol. 2015;6:286. [PMID: 26089823 DOI: 10.3389/fimmu.2015.00286] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
29 Zhao Y, Zhou X. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy. Immunotherapy 2020;12:653-64. [DOI: 10.2217/imt-2019-0139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, Lowdell M, Uharek L, Klingemann H, Curti A, Leung W, Alici E. Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology 2016;5:e1115178. [PMID: 27141397 DOI: 10.1080/2162402X.2015.1115178] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
31 Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, Lim FLWI, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 2021;137:624-36. [PMID: 32902645 DOI: 10.1182/blood.2020007748] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 36.0] [Reference Citation Analysis]
32 Malek E, El-Jurdi N, Kröger N, de Lima M. Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. Front Oncol 2017;7:287. [PMID: 29322027 DOI: 10.3389/fonc.2017.00287] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
33 Shimasaki N, Campana D. Engineering of Natural Killer Cells for Clinical Application. Methods Mol Biol 2020;2097:91-105. [PMID: 31776921 DOI: 10.1007/978-1-0716-0203-4_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barese C, Nguyen T, Abdel-Baki MS, Bollard CM. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy 2017;19:408-18. [PMID: 28109751 DOI: 10.1016/j.jcyt.2016.12.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
35 Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Front Immunol 2020;11:888. [PMID: 32477359 DOI: 10.3389/fimmu.2020.00888] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
36 Bigley AB, Baker FL, Simpson RJ. Cytomegalovirus: an unlikely ally in the fight against blood cancers? Clin Exp Immunol 2018;193:265-74. [PMID: 29737525 DOI: 10.1111/cei.13152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
37 Paul S, Lal G. The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol 2017;8:1124. [PMID: 28955340 DOI: 10.3389/fimmu.2017.01124] [Cited by in Crossref: 158] [Cited by in F6Publishing: 158] [Article Influence: 39.5] [Reference Citation Analysis]
38 Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014;3:1435-1443. [PMID: 25378655 DOI: 10.5966/sctm.2014-0151] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
39 Davies JOJ, Stringaris K, Barrett AJ, Rezvani K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy 2014;16:1453-66. [PMID: 24856895 DOI: 10.1016/j.jcyt.2014.03.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
40 Bachiller M, Battram AM, Perez-Amill L, Martín-Antonio B. Natural Killer Cells in Immunotherapy: Are We Nearly There? Cancers (Basel) 2020;12:E3139. [PMID: 33120910 DOI: 10.3390/cancers12113139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
41 Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, Mc Niece I, Orlowski R, Muñoz-Pinedo C, Bueno C, Menendez P, Fernández de Larrea C, Urbano-Ispizua A, Shpall EJ, Shah N. Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ 2015;22:96-107. [PMID: 25168239 DOI: 10.1038/cdd.2014.120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
42 Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 2017;177:457-66. [PMID: 28295190 DOI: 10.1111/bjh.14570] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 20.5] [Reference Citation Analysis]
43 Medinger M, Lengerke C, Passweg J. Novel therapeutic options in Acute Myeloid Leukemia. Leuk Res Rep 2016;6:39-49. [PMID: 27752467 DOI: 10.1016/j.lrr.2016.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
44 Nayyar G, Chu Y, Cairo MS. Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Front Oncol 2019;9:51. [PMID: 30805309 DOI: 10.3389/fonc.2019.00051] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 23.5] [Reference Citation Analysis]
45 Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant 2018;24:895-908. [PMID: 29339270 DOI: 10.1016/j.bbmt.2018.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
46 Oberschmidt O, Kloess S, Koehl U. Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment. Front Immunol 2017;8:654. [PMID: 28649246 DOI: 10.3389/fimmu.2017.00654] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
47 Zhao X, Cai L, Hu Y, Wang H. Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. Front Immunol 2020;11:584099. [PMID: 33193399 DOI: 10.3389/fimmu.2020.584099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Preethy S, Dedeepiya VD, Senthilkumar R, Rajmohan M, Karthick R, Terunuma H, Abraham SJK. Natural killer cells as a promising tool to tackle cancer-A review of sources, methodologies, and potentials. Int Rev Immunol 2017;36:220-32. [PMID: 28471248 DOI: 10.1080/08830185.2017.1284209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin RE. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant 2016;22:1290-8. [PMID: 27090958 DOI: 10.1016/j.bbmt.2016.04.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 15.0] [Reference Citation Analysis]
50 Vahedi F, Nham T, Poznanski SM, Chew MV, Shenouda MM, Lee D, Ashkar AA. Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells. Sci Rep 2017;7:12083. [PMID: 28935883 DOI: 10.1038/s41598-017-12223-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
51 Matsueda S, Chodon T, Koya RC. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies. Adv Exp Med Biol 2019;1143:217-29. [PMID: 31338822 DOI: 10.1007/978-981-13-7342-8_10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Somanchi SS, Lee DA. Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21. Methods Mol Biol 2016;1441:175-93. [PMID: 27177666 DOI: 10.1007/978-1-4939-3684-7_15] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
53 Vahedi F, Lee AJ, Collins SE, Chew MV, Lusty E, Chen B, Dubey A, Richards CD, Feld JJ, Russell RS, Mossman KL, Ashkar AA. IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. Cytokine 2019;124:154439. [PMID: 29908921 DOI: 10.1016/j.cyto.2018.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
54 Vo MC, Lakshmi TJ, Jung SH, Cho D, Park HS, Chu TH, Lee HJ, Kim HJ, Kim SK, Lee JJ. Cellular immunotherapy in multiple myeloma. Korean J Intern Med 2019;34:954-65. [PMID: 30754964 DOI: 10.3904/kjim.2018.325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
55 Ayello J, Hochberg J, Flower A, Chu Y, Baxi LV, Quish W, van de Ven C, Cairo MS. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy. Exp Hematol 2017;46:38-47. [PMID: 27765614 DOI: 10.1016/j.exphem.2016.10.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
56 Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 2014;26:161-72. [PMID: 24618042 DOI: 10.1016/j.smim.2014.02.002] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 15.1] [Reference Citation Analysis]
57 Burga RA, Khan DH, Agrawal N, Bollard CM, Fernandes R. Designing Magnetically Responsive Biohybrids Composed of Cord Blood-Derived Natural Killer Cells and Iron Oxide Nanoparticles. Bioconjug Chem 2019;30:552-60. [PMID: 30779553 DOI: 10.1021/acs.bioconjchem.9b00048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
58 Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother 2018;41:64-72. [PMID: 29189387 DOI: 10.1097/CJI.0000000000000192] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
59 Scibona E, Morbidelli M. Expansion processes for cell-based therapies. Biotechnol Adv 2019;37:107455. [PMID: 31629791 DOI: 10.1016/j.biotechadv.2019.107455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
60 Lendvai N, Cohen AD, Cho HJ. Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant 2015;50:770-80. [PMID: 25751647 DOI: 10.1038/bmt.2015.5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
61 Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res 2021;27:3744-56. [PMID: 33986022 DOI: 10.1158/1078-0432.CCR-21-0164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Zhang Z, Zhao X, Zhang T, Wang L, Yang L, Huang L, Li F, Liu J, Yue D, Wang F, Li J, Guan F, Xu Y, Zhang B, Zhang Y. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. Cytotherapy 2015;17:86-97. [PMID: 25457278 DOI: 10.1016/j.jcyt.2014.09.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
63 Tomchuck SL, Leung WH, Dallas MH. Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture. Biol Blood Marrow Transplant 2015;21:39-49. [PMID: 25464114 DOI: 10.1016/j.bbmt.2014.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
64 Binsfeld M, Fostier K, Muller J, Baron F, Schots R, Beguin Y, Heusschen R, Caers J. Cellular immunotherapy in multiple myeloma: lessons from preclinical models. Biochim Biophys Acta 2014;1846:392-404. [PMID: 25109893 DOI: 10.1016/j.bbcan.2014.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
65 Sarvaria A, Jawdat D, Madrigal JA, Saudemont A. Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications. Front Immunol 2017;8:329. [PMID: 28386260 DOI: 10.3389/fimmu.2017.00329] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 11.5] [Reference Citation Analysis]
66 Rezvani K, Rouce R, Liu E, Shpall E. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther 2017;25:1769-81. [PMID: 28668320 DOI: 10.1016/j.ymthe.2017.06.012] [Cited by in Crossref: 183] [Cited by in F6Publishing: 177] [Article Influence: 45.8] [Reference Citation Analysis]
67 Fang F, Xiao W, Tian Z. Challenges of NK cell-based immunotherapy in the new era. Front Med 2018;12:440-50. [PMID: 30047028 DOI: 10.1007/s11684-018-0653-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
68 Bachiller M, Perez-Amill L, Battram AM, Carné SC, Najjar A, Verhoeyen E, Juan M, Urbano-Ispizua A, Martin-Antonio B. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. J Immunother Cancer 2021;9:e002866. [PMID: 34433634 DOI: 10.1136/jitc-2021-002866] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One 2018;13:e0191358. [PMID: 29342200 DOI: 10.1371/journal.pone.0191358] [Cited by in Crossref: 35] [Cited by in F6Publishing: 45] [Article Influence: 11.7] [Reference Citation Analysis]
70 Domogala A, Madrigal JA, Saudemont A. Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells. Cytotherapy 2016;18:754-9. [PMID: 27090754 DOI: 10.1016/j.jcyt.2016.02.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
71 Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. Curr Cancer Drug Targets 2020;20:473-89. [PMID: 32357813 DOI: 10.2174/1568009620666200502011059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol 2021;193:216-30. [PMID: 33216984 DOI: 10.1111/bjh.17186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
73 Cairo MS, Tarek N, Lee DA, Delaney C. Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients. Bone Marrow Transplant 2016;51:27-33. [PMID: 26367220 DOI: 10.1038/bmt.2015.196] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
74 Alnabhan R, Madrigal A, Saudemont A. Differential activation of cord blood and peripheral blood natural killer cells by cytokines. Cytotherapy. 2015;17:73-85. [PMID: 25248279 DOI: 10.1016/j.jcyt.2014.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
75 Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother 2018;67:575-87. [DOI: 10.1007/s00262-017-2112-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
76 Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 2021;131:142116. [PMID: 34138753 DOI: 10.1172/JCI142116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
77 Garcia-Aponte OF, Herwig C, Kozma B. Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy. J Biol Eng 2021;15:13. [PMID: 33849630 DOI: 10.1186/s13036-021-00264-7] [Reference Citation Analysis]
78 Garfall AL, Stadtmauer EA. Cellular and vaccine immunotherapy for multiple myeloma. Hematology Am Soc Hematol Educ Program 2016;2016:521-7. [PMID: 27913524 DOI: 10.1182/asheducation-2016.1.521] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
79 Cany J, Dolstra H, Shah N. Umbilical cord blood-derived cellular products for cancer immunotherapy. Cytotherapy 2015;17:739-48. [PMID: 25795272 DOI: 10.1016/j.jcyt.2015.03.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
80 Kannan GS, Aquino-Lopez A, Lee DA. Natural killer cells in malignant hematology: A primer for the non-immunologist. Blood Rev 2017;31:1-10. [PMID: 27665023 DOI: 10.1016/j.blre.2016.08.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
81 Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical Lymphoma Myeloma and Leukemia 2019;19:332-44. [DOI: 10.1016/j.clml.2019.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
82 Mehta RS, Shpall EJ, Rezvani K. Cord Blood as a Source of Natural Killer Cells. Front Med (Lausanne) 2015;2:93. [PMID: 26779484 DOI: 10.3389/fmed.2015.00093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
83 Martín-Antonio B, Suñe G, Perez-Amill L, Castella M, Urbano-Ispizua A. Natural Killer Cells: Angels and Devils for Immunotherapy. Int J Mol Sci 2017;18:E1868. [PMID: 28850071 DOI: 10.3390/ijms18091868] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
84 Etxebeste-Mitxeltorena M, Del Rincón-Loza I, Martín-Antonio B. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. Front Immunol 2021;12:717850. [PMID: 34447383 DOI: 10.3389/fimmu.2021.717850] [Reference Citation Analysis]
85 Hu Z, Xu X, Wei H. The Adverse Impact of Tumor Microenvironment on NK-Cell. Front Immunol 2021;12:633361. [PMID: 34177887 DOI: 10.3389/fimmu.2021.633361] [Reference Citation Analysis]
86 Khan AM, Devarakonda S, Bumma N, Chaudhry M, Benson DM Jr. Potential of NK cells in multiple Myeloma therapy. Expert Rev Hematol 2019;12:425-35. [PMID: 31070067 DOI: 10.1080/17474086.2019.1617128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
87 Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev 2019;290:85-99. [DOI: 10.1111/imr.12793] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
88 Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 2021;14:73. [PMID: 33933160 DOI: 10.1186/s13045-021-01083-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Golden RJ, Fesnak AD. Clinical development of natural killer cells expressing chimeric antigen receptors. Transfus Apher Sci 2021;60:103065. [PMID: 33468407 DOI: 10.1016/j.transci.2021.103065] [Reference Citation Analysis]
90 Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk 2014;14 Suppl:S18-22. [PMID: 25486950 DOI: 10.1016/j.clml.2014.06.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 Quintarelli C, Sivori S, Caruso S, Carlomagno S, Falco M, Boffa I, Orlando D, Guercio M, Abbaszadeh Z, Sinibaldi M, Di Cecca S, Camera A, Cembrola B, Pitisci A, Andreani M, Vinti L, Gattari S, Del Bufalo F, Algeri M, Li Pira G, Moseley A, De Angelis B, Moretta L, Locatelli F. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia 2020;34:1102-15. [DOI: 10.1038/s41375-019-0613-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
92 Xue E, Milano F. Are we underutilizing bone marrow and cord blood? Review of their role and potential in the era of cellular therapies. F1000Res 2020;9:F1000 Faculty Rev-26. [PMID: 31984133 DOI: 10.12688/f1000research.20605.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Russick J, Torset C, Hemery E, Cremer I. NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. Semin Immunol 2020;48:101407. [PMID: 32900565 DOI: 10.1016/j.smim.2020.101407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]